The Current Ratio as of December 2025 (TTM) for Elicera Therapeutics AB (publ) (ELIC.ST) is 3.76

According to Elicera Therapeutics AB (publ)’s latest financial reports and current stock price. The company's current Current Ratio is 3.76. This represents a change of -1.33% compared to the average of 3.81 of the last 4 quarters.

Elicera Therapeutics AB (publ) (ELIC.ST) Historical Current Ratio (quarterly & annually)

How has ELIC.ST Current Ratio performed in the past?

The mean historical Current Ratio of Elicera Therapeutics AB (publ) over the last ten years is 28.64. The current 3.76 Current Ratio has changed 1.21% with respect to the historical average. Over the past ten years (40 quarters), ELIC.ST's Current Ratio was at its highest in in the September 2021 quarter at 35.60. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Elicera Therapeutics AB (publ) (ELIC.ST) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Elicera Therapeutics AB (publ) Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Elicera Therapeutics AB (publ) (ELIC.ST) Average Current Ratio

How has ELIC.ST Current Ratio performed in the past?

The current Current Ratio of Elicera Therapeutics AB (publ) (ELIC.ST) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Elicera Therapeutics AB (publ) (ELIC.ST) Current Ratio vs. Peers

How is ELIC.ST’s Current Ratio compared to its peers?

Elicera Therapeutics AB (publ)’s Current Ratio is greater than Xintela AB (publ) (0.23), less than Intervacc AB (publ) (11.00), greater than Ascelia Pharma AB (publ) (3.60), less than Acarix AB (publ) (9.47), less than Karolinska Development AB (publ) (7.99), greater than Mendus AB (publ) (2.47), greater than Bio-Works Technologies AB (publ) (2.26), greater than Nanexa AB (publ) (2.08), greater than Magle Chemoswed Holding AB (publ) (1.96), less than Initiator Pharma A/S (4.15),

Build a custom stock screener for Elicera Therapeutics AB (publ) (ELIC.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Elicera Therapeutics AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Elicera Therapeutics AB (publ) (ELIC.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Elicera Therapeutics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.